Blue Jet HealthQ2 FY25

Blue Jet Health Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹510.6P/E: 33.9Market Cap: ₹9.7K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Contrast media segment is expected to stabilize and grow in H2 FY25, closing the volume gap seen in H1 2024.
  • New product launches, including an NCE molecule and iodinated product, targeted for Q4 FY25 are expected to improve product mix and revenues.
  • Customer off-take, subdued in calendar year 2024, is anticipated to return to previous levels in the next calendar year.
  • Pharmaceutical intermediates, especially cardiovascular therapy products from Plant 6, are expected to drive strong growth in H2 FY25 with optimal capacity utilization by Q3-Q4.
  • Expansion with 120 KL additional capacity at Unit 2 Ambernath to cater to increased demand in PI and contrast media segments.
  • Unit 3 Mahad plant commissioning planned for Q1 FY26 to further support backward integration and production scaling.
  • Overall, robust demand outlook across all segments with an increasing order book and promising pipeline opportunities.

See what Blue Jet Health management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • The document does not mention any current or planned fundraising through debt or equity.
  • The company maintains a debt-free status with healthy liquidity, holding cash, cash equivalents, and treasury investments totaling INR 3,233 million as of September 2024.
  • Capex plans are ongoing but aligned with existing guidance (~INR 200 crores annually) without indicating new fundraising.
  • Management states they are exploring manufacturing footprint options but have not indicated incremental capex beyond budgeted amounts or the need for external financing.
  • Overall, there is no explicit mention or indication of new debt or equity fundraising in the provided transcript.

See what Blue Jet Health management said on order book — free account, 30 seconds.

Capex plans

Yes
  • The company is on track with its capex plans, maintaining an annual baseline guidance of INR 200 crores.
  • Exploring additional manufacturing footprint options beyond the already budgeted investments.
  • Completed commissioning of Plant 6 at Unit 2 Ambernath, costing INR 900 million, supporting cardiovascular therapy and contrast media segments.
  • Incremental capacity of about 80 KL in the same block is under validation, expected to start commercial supply in Q3 FY '25.
  • Building a small volume plant at Unit 2, aimed for commissioning in Q1 FY '26, intended for proof of concept, regulatory filings, and small GMP validation supplies.
  • Unit 3 at Mahad is being developed to provide backward integration for contrast media; expected to be commercialized in FY '26.
  • Continued investment in R&D infrastructure and talent, including new chemistry platforms like enzymatic and pyrophoric chemistry.
  • Focus on sustainable manufacturing with renewable energy sources supporting about 70% of energy needs.

Track Blue Jet Health — get its next earnings analysis in your feed

How does Blue Jet Health rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisBlue Jet Health
Rev 3Mar 3

How does Blue Jet Health rank in Pharmaceuticals & Biotechnology?

Compare Blue Jet Health against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →